**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 63404

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Facilitators and barriers to colorectal cancer screening in an outpatient setting**

Samuel G *et al*. Determinants of colorectal cancer screening

Gbeminiyi Samuel, MaryKate Kratzer, Oghale Asagbra, Josef Kinderwater, Shiva Poola, Jennifer Udom, Karissa Lambert, Muna Mian, Eslam Ali

**Gbeminiyi Samuel, Karissa Lambert,** Division of Gastroenterology, East Carolina University/Vidant Medical Center, Greenville, NC 27834, United States

**MaryKate Kratzer, Josef Kinderwater, Jennifer Udom,** Department of Internal Medicine, East Carolina University/Vidant Medical Center, Greenville, NC 27834, United States

**Oghale Asagbra,** Department of Health Services and Information Management, East Carolina University, Greenville, NC 27834, United States

**Shiva Poola,** Department of Internal Medicine/Pediatrics, Brody School of Medicine/Vidant Medical Center, Greenville, NC 27834, United States

**Muna Mian,** Department of Internal Medicine, East Carolina University, Greenville, NC 27834, United States

**Eslam Ali,** Department of Gastroenterology and Hepatology, East Carolina University, Greenville, NC 27834, United States

**Author** **contributions:** Samuel G contributed conceptualization, formal analysis, methodology, project administration and writing; Kratzer M contributed project administration, data curation and writing; Asagbra O contributed methodology, formal analysis and software; Kinderwater J, Poola S and Udom J contributed data curation; Lambert K contributed conceptualization and data curation; Mian M contributed supervision; Ali E contributed conceptualization and supervision.

**Corresponding author: MaryKate Kratzer, MD, Doctor,** Department of Internal Medicine, East Carolina University/Vidant Medical Center, 2100 Stantonsburg Road, Greenville, NC 27834, United States. kratzerm19@ecu.edu

**Received:** February 23, 2021

**Revised:** May 7, 2021

**Accepted:** June 1, 2021

**Published online:**

**Abstract**

BACKGROUND

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths in the United States. Still, 1 in 3 adults aged 50 years to 75 years have not been screened for CRC. Early detection and management of precancerous or malignant lesions has been shown to improve overall mortality.

AIM

To determine the most significant facilitators and barriers to CRC screening in an outpatient clinic in rural North Carolina. The results of this study can then be used for quality improvement to increase the rate of patients ages 50 to 75 who are up to date on CRC screening.

METHODS

This retrospective study examined 2428 patients aged 50 years to 75 years in an outpatient clinic. Patients were up to date on CRC screening if they had fecal occult blood test or fecal immunochemical test in the past one year, Cologuard in the past three years, flexible sigmoidoscopy/virtual colonoscopy in the past five years, or colonoscopy in the past ten years. Data on patient socioeconomic status, comorbid conditions, and other determinants of health compliance were included as covariates.

RESULTS

Age [odds ratio (OR) = 1.058; *P* = 0.017], no-show rate percent (OR= 0.962; *P* < 0.05), patient history of obstructive sleep apnea (OR = 1.875; *P* = 0.025), compliance with flu vaccinations (OR = 1.673; *P* < 0.05), compliance with screening mammograms (OR = 2.130; *P* < 0.05), and compliance with screening pap smears (OR = 2.708; *P* < 0.05) were important factors in determining whether a patient will receive CRC screening. Race, gender, insurance or employment status, use of blood thinners, family history of CRC, or other comorbid conditions including diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, and end-stage renal disease were not found to have a statistically significant effect on patient adherence to CRC screening.

CONCLUSION

Patient age, history of sleep apnea, and compliance with other health maintenance tests were significant facilitators to CRC screening, while no-show rate percent was a significant barrier in our patient population. This study will be of benefit to physicians in addressing and improving the CRC screening rates in our community.

**Key Words:** Colorectal cancer screening; Screening colonoscopy; Health maintenance; Colonoscopy; Colorectal cancer; Patient adherence

Samuel G, Kratzer M, Asagbra O, Kinderwater J, Poola S, Udom J, Lambert K, Mian M, Ali E. Facilitators and barriers to colorectal cancer screening in an outpatient setting. *World J Clin Cases* 2021; In press

**Core Tip:** Only about 2 of 3 adults from ages 50 to 75 are up-to-date with colorectal cancer screening. Factors which influenced screening adherence included patient age, history of obstructive sleep apnea, clinic no-show rate and adherence to other health screening exams. Gender, ethnicity, tobacco use, and other common comorbid conditions did not correlate with the rate of colorectal cancer screening adherence.

**INTRODUCTION**

Colorectal cancer (CRC) is the fourth most common cancer[1] and the second leading cause of cancer-related deaths[2] in the United States. The U.S. Preventive Services Task Force recommends screening average-risk adults who are between 50 years and 75 years old for CRC. Despite this recommendation, less than 70% of eligible adults in the United States were up-to-date on CRC screening in 2018[2]. Groups who were less likely to be screened include Hispanics, American Indians, Alaska Natives, people who are 50 years to 64 years old, those who don’t live in a city, and who belong to a lower socioeconomic status[2]. Lower rates of screening are associated with cancer deaths. Estimated value of life lost due to cancer deaths in the United States is significant and projected to rise, even if mortality rates remain constant, because of anticipated population changes[3]. However, projected annual decreases of cancer mortality rates of 2% reduced the expected value of life lost in the year 2020 from $140.1 billion to $93.5 billion for CRC[3].

Screening helps to identify precancerous polyps, so they can be excised before turning into cancer. Screening also detects CRC at an early stage, when treatment often leads to a cure. Risk factors for CRC include tobacco use, obesity, sedentary lifestyle, Western diet, as well as consumption of red meat[4]. Nevertheless, medications such as aspirin and postmenopausal hormones for women are associated with marked reductions in CRC risk, though their utility may be limited by associated risks[4]. The incidence and overall mortality of CRC in patients over the age of 55 has been down-trending over the past several decades, which is in part due to improved screening and subsequent early detection and removal of precancerous lesions[5].

There are multiple acceptable forms of CRC screening: guaiac-based fecal occult blood testing (FOBT), fecal immunohistochemical testing (FIT), multitarget stool DNA test (Cologuard), virtual colonoscopy [computed tomography (CT) colonography], flexible sigmoidoscopy, and colonoscopy[5,6]. Stool-based testing including FOBT, FIT, and Cologuard are useful, noninvasive screening tests which can identify patients who are in need of further endoscopic surveillance, and if negative can allow patients to avoid an invasive procedure. FOBT detects peroxidase activity of the heme portion of hemoglobin. While this form of screening is convenient for patients, there is a high risk for false-positives caused by ingestion of red meats, fruits or vegetables[6]. FOBT also does not differentiate upper gastrointestinal bleeding from colonic bleeding. FIT, however, detects the globin component of hemoglobin. This test is not influenced by diet and is more specific for lower gastrointestinal bleeding, as globin from the upper gastrointestinal tract is degraded prior to being expelled in feces. Both FOBT and FIT are recommended yearly for CRC screening. Cologuard is a multi-target stool DNA test which detects hemoglobin as well as inappropriately methylated proteins which are commonly found with CRC. These features make Cologuard significantly more sensitive for CRC (92.3%) compared to FIT (73.8%)[5]. Cologuard should be performed every 3 years for CRC screening.

Virtual colonoscopy is another less invasive approach to CRC screening and is recommended at a longer interval of every 5 years[7]. This test involves the same bowel regimen as a colonoscopy, but does not require anesthesia. In this test, CT is used to examine the lumen of the colon and rectum for abnormal growths, much like colonoscopy. In fact, CRC detection rate is similar to colonoscopy with adequate bowel preparation. Johnson *et al*[7] determined that the sensitivity for detecting adenomas and malignancies > 10 mm was equal to that of colonoscopy, however these values decreased with smaller sized lesions. The most prominent drawbacks to this examination are its relative inability to detect polyps smaller than 5-6 mm, as well as its lack of therapeutic intervention. A patient with positive virtual colonoscopy will need to undergo same-day colonoscopy or repeat the bowel preparation for confirmatory and therapeutic colonoscopy at a later date. CT colonography can also exhibit incidental extracolonic findings which may need to further unnecessary testing for the patient[7].

Flexible sigmoidoscopy is an endoscopic technique which allows for direct visualization and therapeutic resection of adenomas or malignancies located in the rectum or left-sided colon. This test requires a less cumbersome bowel regimen compared to colonoscopy and has adequate CRC detection rates distal to the splenic flexure. This test does not visualize the right-sided colon, however, and therefore carries a risk of missed malignancies proximal to its visual field. Flexible sigmoidoscopy is an acceptable form of CRC screening and should be repeated every 5 years. Finally, colonoscopy is the gold standard for CRC screening. This is mostly due to its direct visualization of premalignant or malignant lesions and combined diagnostic and therapeutic capabilities. This modality examines the entire colon as well as the cecum. It does require a full bowel preparation as well as anesthesia, and therefore can be inconvenient for patients. Other risks involve perforation, post-polypectomy bleeding, and post-polypectomy syndrome. As a result of its high detection rates with a proper bowel regimen, patients with normal screening colonoscopies are considered up-to-date for CRC screening for 10 years[5,6].

Vidant Health is a not-for-profit, 1447-bed hospital system that serves more than 1.4 million people in 29 Eastern North Carolina counties. The health system is made up of nine hospitals which provide services to a sizable number of patients who don’t live in a city and who often belong to a low socioeconomic status. Given the potential for health disparity in this unique group of patients, we decided to embark on a study to assess the screening rate amongst our patient population.

**MATERIALS AND METHODS**

IRB-approved (UMCIRB 19-000848) retrospective review of electronic medical records (EMR) was conducted for patients ages 50 years to 75 years who were seen in the East Carolina University Internal Medicine clinic between July 1, 2018 and June 30, 2019. Eligible adults were considered up-to-date with CRC screening if they had documentation of FOBT or FIT performed in the past 1 year, Cologuard in the past 3 years, flexible sigmoidoscopy or virtual colonoscopy in the past 5 years, or colonoscopy in the past 10 years. For each patient included in the study, the demographic variables collected included age (recorded as integers from 50-75), gender (male, female, unknown/not reported), race (White/Caucasian, Black/African American, Hispanic, Asian, Native American/Alaska native, Native Hawaiian or other Pacific Islander, more than one race/unknown/not reported), marital status (married, not married, divorced, widowed, unknown), family history of CRC (yes/no), smoking status (prior smoker, current smoker, never smoker) and information suggestive of socioeconomic status such as employment status (employed/unemployed/unknown), insurance status (private insurance/public insurance/uninsured), level of education (no formal education/high school or equivalent/college or above/not reported), and travel distance to clinic (in miles, calculated using zip code in Google Maps).

Common comorbidities such as hypertension, diabetes mellitus, congestive heart failure, end-stage renal disease on hemodialysis or peritoneal dialysis, obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease were also included if previously documented within the EMR. The use of aspirin was also assessed. Post-graduate year (PGY) level of training of the most recent provider (PGY1/PGY2/PGY3/PGY4/PGY5/fellow/attending) was also documented. Finally, data suggestive of overall healthcare adherence such as no-show rate (percentage of missed visits out of all scheduled visits as listed in Epic EMR) and compliance with influenza vaccine, screening Papanicolaou exam, and screening mammogram (up-to-date at time of qualifying visit) were collected and stored in a secure RedCap database. A logistic regression model was then constructed to determine which of these variables would serve as facilitators or barriers to CRC screening. This multivariate analysis was performed using STATA v.15. Only statistically significant results (*P* < 0.05) are discussed.

**RESULTS**

Total 2428 patients were included in this retrospective cross-sectional study. Table 1 presents the frequency distributions, mean, and standard deviation (where appropriate), showing the characteristics of patients included in the sample. Majority of patients, 66.9% (*n* = 1624), were up-to-date on CRC screening. Data on the type of CRC screening test performed were available for 1618 of 1624 patients who were up-to-date. In this subset of patients, 92.82% (*n* = 1502) had their CRC screening performed *via* colonoscopy, 2.97% (*n* = 48) were screened using Cologuard, 1.79% (*n* = 29) were screened using flexible sigmoidoscopy, 1.42% (*n* = 23) had documented screening with FOBT, and 0.99% (*n* = 16) were screened with CT Colonography.

The study sample was made up of 53.6% females and 46.4% males. The median age was 61 years. The majority of patients were Black/African American (60.9%, *n* = 1479) followed by White/Caucasian (35.5%, *n* = 861), Hispanic (1.6%, *n* = 38), and less than 1% of the study population were Asian, American Indian/Alaska native, Native Hawaiian/Pacific Islander. 39 patients were documented as multiple ethnicities or did not have ethnicity recorded. Nearly half of the patients were married (45.3%). 26.6% were not married, 18.4% divorced, and 9.1% were widowed. Family history of CRC was documented in 8.7% (*n* = 212) patients.

As Table 2 shows, the logistics regression analysis revealed that age [odds ratio (OR) = 1.058; *P* = 0.017], no-show rate percent (OR = 0.962; *P* < 0.05), patient history of OSA (OR = 1.875; *P* = 0.025), compliance with flu vaccinations (OR = 1.673; *P* < 0.05), compliance with screening mammograms (OR = 2.130; *P* < 0.05), and compliance with screening pap smears (OR = 2.708; *P* < 0.05) were significant factors in determining whether a patient will receive CRC screening.

**DISCUSSION**

Barriers experienced by patients influence their receptiveness of CRC screening. In a 2005 study, primary care physicians and patients completed a survey which ranked barriers to CRC screening. Patients believed their lack of awareness and limited knowledge of CRC and screening methods were the most noteworthy barriers[8]. Both physicians and patients ranked patient-related barriers as the most significant. Similarly, Jones *et al*[9] determined through mail-out surveys and focus groups that patients considered their own lack of knowledge regarding CRC and screening as a major barrier. Many participants felt as though they didn’t fully understand their instructions, both for at-home FOBT as well as pre-procedure bowel preparation. Furthermore, patients shared many misconceptions about CRC which were holding them back from screening. Some patients preferred to remain ignorant about their colon health because they considered CRC as a death sentence due to past experiences with sick family members. While death rates are declining in patients > 55, they are increasing in patients < 55[10]. Our study aligns with this information, as increasing age was associated with greater adherence to CRC screening. Knowing this, there is a pressing need to determine, and overcome the barriers to screening, in order to increase CRC screening rates in all patients ages 50 to 75.

Embarrassment and fear were barriers which were reported by physicians and patients, although fear was more commonly reported by females than males[8,9]. Patients were able to expand upon these factors in focus groups, stating that the topic of colonoscopy or manipulating their own stool for home FOBT was a taboo topic compared to other cancer screening tests; conversely, though, our study showed that patients who were up-to-date on other health maintenance including screening mammogram, screening pap smear, and annual influenza vaccination were more likely to be up-to-date with CRC screening. Some male participants suggested that colonoscopies took away their manhood. They not only feared the invasive procedure itself, but also pain associated with colonoscopy/sigmoidoscopy, possible diagnosis of CRC, and uncomfortable bowel preparation.

Another possible barrier discussed in other studies was the providers’ failure to recommend CRC screening. In the study by Klabunde *et al*[8], provider’s failure to recommend CRC screening as a significant barrier. Conversely, Jones *et al*[9] reported only 5 of 317 participants reported lack of physician recommendation as a barrier to CRC screening. Gennarelli *et al*[11] tested providers on their knowledge of the American Cancer Society recommendations for CRC screening. Medical students answered only 32% of questions correctly, residents scored 49%, and attending physicians scored 56%. With the notion that increased knowledge of the recommendations for CRC screening should align with higher screening rates, we studied the level of provider training to determine if more experienced physicians were more likely to enforce CRC screening. There was no significant relationship between provider level of training and patient compliance with CRC screening in our patient population.

Neither of the above studies mentioned comorbidities which could play a role in adherence to CRC screening. Our study showed that a history of OSA was a significant facilitator to CRC screening. One thought as to why these patients are more adherent with CRC screening is that patients with OSA likely have other underlying comorbidities related to obesity and therefore visit their primary care physicians more frequently. This gives the patient more opportunities to be counseled by their doctor(s) about the importance of CRC screening. More evidence for this hypothesis is the inverse relationship between patient no-show rate and CRC screening adherence in our study. Less visits to the patient’s primary care doctor results in less adherence to CRC screening. Another thought is that in order to have a diagnosis of OSA, the patient must have completed a sleep study; if a patient is adherent with this type of testing, then perhaps he or she is adherent to other testing, such as CRC screening. This again is supported by our finding that patients are more likely to be compliant with CRC screening if they are up-to-date on other healthcare maintenance. These studies, along with our own, show us that there are a multitude of reasons why patients do or do not adhere with CRC screening.

**CONCLUSION**

This study revealed that the age of patient, history of sleep apnea, compliance with other health maintenance tests were significant facilitators to CRC screening, while no-show rate percent was a significant barrier in this patient population. The overarching goal of this study is to enlighten physicians to these barriers, and ultimately improve adherence to CRC screening.

**ARTICLE HIGHLIGHTS**

***Research background***

Colorectal cancer (CRC) remains the third most common cancer in the United States. With appropriate screening, early lesions can be identified before they have developed into malignancy. Unfortunately, only about 2 of 3 Americans between the ages of 50 and 75 are up to date on CRC screening. We developed this study to determine the barriers and facilitators to CRC screening.

***Research motivation***

By completing this study, we aimed to determine which factors lead to increased or decreased adherence to CRC screening in our patients. By learning these facilitators or barriers to screening, we can implement practices to increase screening rates and hopefully decrease rates of CRC.

***Research objectives***

The main objective was determining facilitators and barriers to CRC screening. As we established these factors, we are opening our minds to changes that can be generalized to all cancer screening tests, to make a difference in our communities.

***Research methods***

We performed a retrospective analysis, reviewing the electronic medical records for every patient between the ages of 50 and 75 who visited our internal medicine clinic in a 1-year period. We recorded data pertaining to demographics, comorbid conditions, and adherence with other medical screening tests to look for correlations with screening adherence or nonadherence. Multivariate analysis was performed using STATA v. 15.

***Research results***

Advanced age was associated with increased adherence to CRC screening. A diagnosis of obstructive sleep apnea was also associated with increased adherence to CRC screening, but no other comorbid condition shared this finding. Higher no-show rates to the clinic was consistent with lower CRC screening adherence. Finally, adherence with other health maintenance screenings was associated with increased adherence with CRC screening.

***Research conclusions***

We concluded that patients with obstructive sleep apnea likely had multiple providers who encouraged screening for CRC, and were compliant with other outpatient studies (sleep studies for example) which may be why these patients had higher rates of CRC screening. With advanced age likely comes more frequent visits to the physician and hence more opportunities for counseling on cancer screening tests. Conversely, if a patient has a high no-show rate to routine clinic appointments, then they likely will also have poor adherence to screening tests and have less counseling on the importance of these tests. Finally, if a patient is adherent with other health maintenance exams like mammograms or pap smears, then they likely will also be adherent to screening for CRC.

***Research perspectives***

We now know some of the factors that influence adherence to CRC screening. Future research should focus on those patients who are not up-to-date on screening, and determine what personal, religious, or physician-related factors have kept them from completing CRC screening.

**REFERENCES**

1 **Centers for Disease Control and Prevention**. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017). [cited 27 June 2020]. In: Centers for Disease Control and Prevention [Internet]. Available from: www.cdc.gov/cancer/dataviz

2 **Centers for Disease Control and Prevention**. Colorectal Cancer Control Program (CRCCP). [cited 24 September 2020]. In: Centers for Disease Control and Prevention [Internet]. Available from: https://www.cdc.gov/cancer/crccp/about.htm

3 **Yabroff KR**, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ. Estimates and projections of value of life lost from cancer deaths in the United States. *J Natl Cancer Inst* 2008; **100**: 1755-1762 [PMID: 19066267 DOI: 10.1093/jnci/djn383]

4 **Chan AT**, Giovannucci EL. Primary prevention of colorectal cancer. *Gastroenterology* 2010; **138**: 2029-2043.e10 [PMID: 20420944 DOI: 10.1053/j.gastro.2010.01.057]

5 **Wolf AMD**, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin* 2018; **68**: 250-281 [PMID: 29846947 DOI: 10.3322/caac.21457]

6 **Levin B**, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA Cancer J Clin* 2008; **58**: 130-160 [PMID: 18322143 DOI: 10.3322/CA.2007.0018]

7 **Johnson CD**, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ. Accuracy of CT colonography for detection of large adenomas and cancers. *N Engl J Med* 2008; **359**: 1207-1217 [PMID: 18799557 DOI: 10.1056/NEJMoa0800996]

8 **Klabunde CN**, Vernon SW, Nadel MR, Breen N, Seeff LC, Brown ML. Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. *Med Care* 2005; **43**: 939-944 [PMID: 16116360 DOI: 10.1097/01.mlr.0000173599.67470.ba]

9 **Jones RM**, Devers KJ, Kuzel AJ, Woolf SH. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. *Am J Prev Med* 2010; **38**: 508-516 [PMID: 20409499 DOI: 10.1016/j.amepre.2010.01.021]

10 **Siegel RL**, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, Jemal A. Colorectal Cancer Incidence Patterns in the United States, 1974-2013. *J Natl Cancer Inst* 2017; **109**: djw322 [PMID: 28376186 DOI: 10.1093/jnci/djw322]

11 **Gennarelli M**, Jandorf L, Cromwell C, Valdimarsdottir H, Redd W, Itzkowitz S. Barriers to colorectal cancer screening: inadequate knowledge by physicians. *Mt Sinai J Med* 2005; **72**: 36-44 [PMID: 15682261]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the East Carolina University Institutional Review Board (approval No. UMCIRB 19-000848).

**Informed consent statement:** Due to the retrospective nature of this study, waiver for informed consent was approved.

**Conflict-of-interest statement:** There is no conflict of interest to report.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February 23, 2021

**First decision:** April 18, 2021

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chou YC **S-Editor:** Gao CC **L-Editor: P-Editor:**

**Table 1 Characteristics of patients in study**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Categories** | **Patients who were up-to-date on CRC screening** | **Patients in study *n* (%)** |
| **No** | **Yes** | **Total = 2424** |
| Age (yr)b | Mean ± SD | 60.23 ± 7.12 | 62.05 ± 6.77 | 61.45 ± 6.94 |
| No-show rateb | Mean ± SD | 13.75 ± 12.08 | 8.43 ± 8.33 | 10.19 ± 10.05 |
| History of COPD | No | 725 | 1486 | 2211 (91.21) |
| Yes | 77 | 136 | 213 (8.79) |
| History of CHFa | No | 686 | 1439 | 2125 (87.67) |
| Yes | 116 | 183 | 299 (12.33) |
| History of diabetes | No | 506 | 1000 | 1506 (62.13) |
| Yes | 296 | 622 | 918 (37.87) |
| History of hypertension | No | 203 | 382 | 585 (24.13) |
| Yes | 599 | 1240 | 1839 (75.87) |
| History of ESRD on dialysis (HD or PD) | No | 777 | 1584 | 2361 (97.4) |
| Yes | 25 | 38 | 63 (2.60) |
| History of OSAb | No | 685 | 1299 | 1984 (81.85) |
| Yes | 117 | 323 | 440 (18.15) |
| Use of blood thinners | No | 384 | 749 | 1133 (46.74) |
| Yes | 418 | 873 | 1291 (53.26) |
| Smoking statusb | Current smoker | 214 | 291 | 505 (20.83) |
| Former smoker | 269 | 645 | 914 (37.71) |
| Never smoker | 319 | 686 | 1005 (41.46) |
| Family history of colorectal cancerb | No | 750 | 1462 | 2212 (91.25) |
| Yes | 52 | 160 | 212 (8.75) |
| Compliance with flu vaccinationb | No | 390 | 486 | 876 (36.14) |
| Yes | 412 | 1136 | 1548 (63.86) |
| Compliance with mammogramb | No | 193 | 150 | 343 (27.75) |
| Yes | 237 | 656 | 893 (72.25) |
| Compliance with screening papb | No | 162 | 119 | 281 (42.38) |
| Yes | 103 | 279 | 382 (57.62) |
| Race/ethnicitya | White | 278 | 582 | 860 (35.48) |
| Black/African America | 483 | 994 | 1477 (60.93) |
| Hispanic | 17 | 21 | 38 (1.57) |
| Asian | 2 | 7 | 9 (0.37) |
| American Indian/Alaska Native | 1 | 1 | 2 (0.08) |
| More than one race/unknown/not reported | 21 | 17 | 38 (1.57) |
| Gender | Male | 351 | 775 | 1126 (46.47) |
| Female | 451 | 846 | 1297 (53.53) |
| Employment statusa | Employed | 236 | 561 | 797 (32.88) |
| Unemployed | 197 | 405 | 602 (24.83) |
| Unknown | 369 | 656 | 1025 (42.29) |
| Education | College or above | 26 | 66 | 92 (3.80) |
| High school/equivalent | 65 | 125 | 190 (7.84) |
| No formal education | 16 | 32 | 48 (1.98) |
| Unknown/not reported | 695 | 1,399 | 2094 (86.39) |
| Insurance statusb | Private insurance | 273 | 640 | 913 (37.67) |
| Public insurance (medicaid/medicare) | 465 | 938 | 1403 (57.88) |
| Uninsured | 64 | 44 | 108 (4.46) |
| Marital statusa | Married | 334 | 763 | 1097 (45.26) |
| Divorced | 153 | 294 | 447 (18.44) |
| Not married | 237 | 408 | 645 (26.61) |
| Widowed | 70 | 149 | 219 (9.03 |
| Unknown | 8 | 8 | 16 (0.66) |

Chi-square test was used with categorical variables and two sample T-test was used with continuous variables. a*P* < 0.05; b*P* < 0.01. CRC: Colorectal cancer; OSA: Obstructive sleep apnea; COPD: Chronic obstructive pulmonary disease; CHF: Congestive heart failure; ESRD: End-stage renal disease; HD: Hemodialysis; PD: Peritoneal dialysis.

**Table 2 Logistic regression showing facilitators or barriers to colorectal cancer screening**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Odds ratio** | **95% confidence interval** |
| Age (yr) | 1.0581a | 1.0103 | 1.1083 |
| Race ethnicity (ref: White/ Caucasian) |  |  |  |
| Black/African American | 1.0562 | 0.6759 | 1.6506 |
| Hispanic | 0.9418 | 0.1601 | 5.5396 |
| More than one race/unknown/not reported | 0.5142 | 0.1084 | 2.4391 |
| Employment status (ref: employed) |  |  |  |
| Unemployed | 0.7664 | 0.4316 | 1.3611 |
| Unknown | 0.7667 | 0.4855 | 1.2107 |
| Years of Education (ref: college or above) |  |  |  |
| High school/equivalent | 1.1055 | 0.3516 | 3.4761 |
| No formal education | 1.3413 | 0.2381 | 7.5564 |
| Unknown/not reported | 1.4783 | 0.5826 | 3.7509 |
| Insurance status (ref: Private insurance) |  |  |  |
| Public insurance (Medicaid/Medicare) | 1.1679 | 0.7422 | 1.8377 |
| Uninsured | 0.5161 | 0.2420 | 1.1006 |
| Provider Years of Training (ref: attending) |  |  |  |
| Resident PGY1 | 0.7212 | 0.3967 | 1.3113 |
| Resident PGY2 | 1.1487 | 0.6445 | 2.0473 |
| Resident PGY3 | 0.6222 | 0.3733 | 1.0370 |
| Resident PGY4 | 0.5764 | 0.1727 | 1.9234 |
| No-show rate percent | 0.9616b | 0.9444 | 0.9793 |
| Marital status (ref: married) |  |  |  |
| Divorced | 0.8826 | 0.5257 | 1.4819 |
| Not married | 0.9425 | 0.5921 | 1.5002 |
| Unknown | 0.5473 | 0.0920 | 3.2549 |
| Widowed | 0.7585 | 0.3632 | 1.5840 |
| History of COPD |  |  |  |
| Yes | 0.5648 | 0.2816 | 1.1328 |
| History of diabetes |  |  |  |
| Yes | 1.1078 | 0.7182 | 1.7088 |
| History of CHF |  |  |  |
| Yes | 0.6007 | 0.3131 | 1.1527 |
| History of hypertension |  |  |  |
| Yes | 0.9223 | 0.5936 | 1.4328 |
| History of ESRD on dialysis HD or PD |  |  |  |
| Yes | 0.6247 | 0.1291 | 3.0223 |
| History of OSA |  |  |  |
| Yes | 1.8752a | 1.0838 | 3.2444 |
| Use of blood thinners |  |  |  |
| Yes | 1.0809 | 0.7148 | 1.6345 |
| Family history of colorectal cancer |  |  |  |
| Yes | 0.9013 | 0.4736 | 1.7154 |
| Smoking status (ref: current smoker) |  |  |  |
| Former smoker | 0.9741 | 0.5849 | 1.6223 |
| Never smoker | 0.9415 | 0.5697 | 1.5559 |
| Compliance with flu vaccination |  |  |  |
| Yes | 1.6729a | 1.1255 | 2.4867 |
| Compliance with mammogram |  |  |  |
| Yes | 2.1295b | 1.3904 | 3.2614 |
| Compliance with screening pap |  |  |  |
| Yes | 2.7081b | 1.8213 | 4.0267 |
| Travel distance from clinic | 1.0016 | 0.9996 | 1.0037 |

a*P* < 0.05; b*P* < 0.01. PGY: Post-graduate year; OSA: Obstructive sleep apnea; COPD: Chronic obstructive pulmonary disease; CHF: Congestive heart failure; ESRD: End-stage renal disease; HD: Hemodialysis; PD: Peritoneal dialysis.